Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares IssuedShort-Term Debt repayments
Ratios

BeOne Medicines (BEIGF) Receivables - Net (2017 - 2025)

BeOne Medicines (BEIGF) has disclosed Receivables - Net for 9 consecutive years, with $865.1 million as the latest value for Q4 2025.

  • Quarterly Receivables - Net rose 27.92% to $865.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $865.1 million through Dec 2025, up 27.92% year-over-year, with the annual reading at $865.1 million for FY2025, 27.92% up from the prior year.
  • Receivables - Net for Q4 2025 was $865.1 million at BeOne Medicines, roughly flat from $863.3 million in the prior quarter.
  • The five-year high for Receivables - Net was $865.1 million in Q4 2025, with the low at $73.8 million in Q2 2021.
  • Average Receivables - Net over 5 years is $409.9 million, with a median of $333.8 million recorded in 2023.
  • The sharpest move saw Receivables - Net soared 699.82% in 2021, then crashed 64.16% in 2022.
  • Over 5 years, Receivables - Net stood at $483.1 million in 2021, then plummeted by 64.16% to $173.2 million in 2022, then surged by 106.75% to $358.0 million in 2023, then skyrocketed by 88.89% to $676.3 million in 2024, then increased by 27.92% to $865.1 million in 2025.
  • According to Business Quant data, Receivables - Net over the past three periods came in at $865.1 million, $863.3 million, and $770.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.